<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091182</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01815</org_study_id>
    <secondary_id>ADVL0421</secondary_id>
    <secondary_id>COG-ADVL0421</secondary_id>
    <secondary_id>CDR0000384560</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT00091182</nct_id>
  </id_info>
  <brief_title>Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment</brief_title>
  <official_title>A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well oxaliplatin works in treating young patients with&#xD;
      recurrent solid tumors that have not responded to previous treatment. Drugs used in&#xD;
      chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing&#xD;
      so they stop growing or die.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the response rate in children with recurrent or refractory solid tumors treated&#xD;
      with oxaliplatin.&#xD;
&#xD;
      II. Determine the cumulative toxicity of this drug in these patients. III. Determine the&#xD;
      pharmacokinetic profile of this drug in these patients. IV. Determine time to progression and&#xD;
      overall survival of patients treated with this drug.&#xD;
&#xD;
      V. Correlate the extent of oxaliplatin exposure with response in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to disease type.&#xD;
&#xD;
      Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up&#xD;
      to 17 courses in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Response rate and confidence intervals will be constructed according to the method of Chang and O'Brien.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Childhood Central Nervous System Germ Cell Tumor</condition>
  <condition>Childhood Extragonadal Germ Cell Tumor</condition>
  <condition>Childhood Hepatoblastoma</condition>
  <condition>Childhood Hepatocellular Carcinoma</condition>
  <condition>Childhood High-grade Cerebral Astrocytoma</condition>
  <condition>Childhood Low-grade Cerebral Astrocytoma</condition>
  <condition>Childhood Malignant Ovarian Germ Cell Tumor</condition>
  <condition>Childhood Malignant Testicular Germ Cell Tumor</condition>
  <condition>Childhood Teratoma</condition>
  <condition>Recurrent Adrenocortical Carcinoma</condition>
  <condition>Recurrent Childhood Brain Stem Glioma</condition>
  <condition>Recurrent Childhood Cerebellar Astrocytoma</condition>
  <condition>Recurrent Childhood Cerebral Astrocytoma</condition>
  <condition>Recurrent Childhood Ependymoma</condition>
  <condition>Recurrent Childhood Liver Cancer</condition>
  <condition>Recurrent Childhood Malignant Germ Cell Tumor</condition>
  <condition>Recurrent Childhood Rhabdomyosarcoma</condition>
  <condition>Recurrent Childhood Soft Tissue Sarcoma</condition>
  <condition>Recurrent Childhood Visual Pathway and Hypothalamic Glioma</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Nasopharyngeal Cancer</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Recurrent Osteosarcoma</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Recurrent Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin IV over 2 hours on day 1. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed* solid tumor, including any of the following:&#xD;
&#xD;
               -  Ewing's sarcoma/peripheral primitive neuroectodermal tumor (PNET)&#xD;
&#xD;
               -  Osteosarcoma&#xD;
&#xD;
               -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Neuroblastoma&#xD;
&#xD;
               -  High-grade astrocytoma&#xD;
&#xD;
               -  Low-grade astrocytoma&#xD;
&#xD;
               -  Glioblastoma multiforme&#xD;
&#xD;
               -  Ependymoma&#xD;
&#xD;
               -  Hepatoblastoma&#xD;
&#xD;
               -  Germ cell tumors of any site&#xD;
&#xD;
               -  Rare tumors of interest, including any of the following:&#xD;
&#xD;
                    -  Soft tissue sarcoma&#xD;
&#xD;
                    -  Hepatocellular carcinoma&#xD;
&#xD;
                    -  Childhood/adolescent colorectal carcinoma&#xD;
&#xD;
                    -  Childhood/adolescent renal cell carcinoma&#xD;
&#xD;
                    -  Childhood/adolescent adrenocortical carcinoma&#xD;
&#xD;
                    -  Childhood/adolescent nasopharyngeal carcinoma&#xD;
&#xD;
          -  Recurrent disease OR refractory to conventional therapy&#xD;
&#xD;
          -  Measurable disease by clinical exam, CT scan, MRI, or positron emission tomography&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100% (for patients over age 10)&#xD;
&#xD;
          -  Performance status - Lansky 50-100% (for patients age 10 and under)&#xD;
&#xD;
          -  At least 8 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3*&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mm^3* (transfusion independent)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL* (RBC transfusions allowed)&#xD;
&#xD;
          -  Granulocytopenia, anemia, and/or thrombocytopenia due to bone marrow metastases or&#xD;
             extensive prior radiotherapy allowed provided the above hematological criteria are met&#xD;
&#xD;
          -  Bilirubin ≤ 3 mg/dL&#xD;
&#xD;
          -  Creatinine based on age as follows:&#xD;
&#xD;
               -  ≤ .8 mg/dL (for patients age 5 and under)&#xD;
&#xD;
               -  ≤ 1.0 mg/dL (for patients age 6 to 10)&#xD;
&#xD;
               -  ≤ 1.2 mg/dL (for patients age 11 to 15)&#xD;
&#xD;
               -  ≤1.5 mg/dL (for patients age 16 to 21)&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate &gt; 20 mL/min&#xD;
&#xD;
          -  No uncontrolled seizure disorder&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  CNS toxicity ≤ grade 2&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  At least 7 days since prior anticancer biologic therapy&#xD;
&#xD;
          -  More than 1 week since prior growth factors&#xD;
&#xD;
          -  At least 6 months since prior allogeneic stem cell transplantation&#xD;
&#xD;
               -  No evidence of active graft-vs-host disease&#xD;
&#xD;
          -  No concurrent immunomodulating agents&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  No prior oxaliplatin&#xD;
&#xD;
          -  Prior carboplatin or cisplatin allowed&#xD;
&#xD;
          -  More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
          -  Concurrent dexamethasone for CNS tumors allowed provided patient has been on a stable&#xD;
             or decreasing dose for ≥ 1 week before study entry&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior local palliative radiotherapy (small port)&#xD;
&#xD;
          -  At least 6 months since prior craniospinal radiotherapy&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy to ≥ 50% of the pelvis&#xD;
&#xD;
          -  At least 6 weeks since other prior substantial radiotherapy to the bone marrow&#xD;
&#xD;
          -  Concurrent radiotherapy to localized painful lesions allowed provided ≥ 1 measurable&#xD;
             lesion is not irradiated&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Orren Beaty</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Oncology Group</name>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <zip>91006-3776</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Ependymoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Teratoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
    <mesh_term>Hepatoblastoma</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

